Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. Lynch syndrome accounts for 1–3 % of patients developing colorectal cancer. This autosomal dominant disorder is caused by germline mutations in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. A mutation in one of these genes is characterised by the development of CRC and various other associated cancers at an early age. The diagnosis of Lynch syndrome has evolved over the last two decades to include family history, tumour histopathological characteristics, immunohistochemistry, testing for microsatellite instability as well as germline genetic testing as modalities for making the diagnosis. By identifying families and individuals with Lynch syndrome, individuals can be enrolled in focussed screening programmes that have been shown to decrease mortality from colorectal cancer. In this chapter we define the terms “HNPCC”, “Lynch syndrome” and “Familial colorectal cancer syndrome X” and discuss the different diagnostic modalities. We propose a logical and cost-effective algorithm to diagnose Lynch syndrome, by appropriately using all the diagnostic modalities in the at-risk individual.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29. doi:10.3322/caac.20138; 10.3322/caac.20138
Jass JR (2005) What’s new in hereditary colorectal cancer? Arch Pathol Lab Med 129:1380–1384. doi:10.1043/1543-2165(2005)129
Hampel H, Frankel WL, Martin E et al (2005) Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860. doi:10.1056/NEJMoa043146
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932. doi:10.1056/NEJMra012242
Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of lynch syndrome (hereditary non-polyposis cancer). J Med Genet 4:353–362. doi:10.1136/jmg.2007.048991
Moreira L, Balaguer F, Lindor N et al (2012) Identification of lynch syndrome among patients with colorectal cancer. JAMA 308:1555–1565. doi:10.1001/jama.2012.13088; 10.1001/jama.2012.13088
Stupart DA, Goldberg PA, Algar U, Ramesar R (2009) Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 11:126–130. doi:10.1111/j.1463-1318.2008.01702.x; 10.1111/j.1463-1318.2008.01702.x
Stoffel EM, Chittenden A (2010) Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. Gastroenterology 139:1436–1441, 1441.e1. doi:10.1053/j.gastro.2010.09.018
Bonadona V, Bonaiti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome. JAMA 305:2304–2310. doi:10.1001/jama.2011.743
Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456
Wijnen JT, Vasen HF, Khan PM et al (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339:511–518. doi:10.1056/NEJM199808203390804
Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641–645
de Leon MP, Pedroni M, Benatti P et al (2011) Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut 45:32–38
Goodenberger M, Lindor NM (2011) Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 45:488–500. doi:10.1097/MCG.0b013e318206489c; 10.1097/MCG.0b013e318206489c
Jass JR (2006) Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol 12:4943–4950
Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425
Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762
Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073–2087.e3. doi:10.1053/j.gastro.2009.12.064; 10.1053/j.gastro.2009.12.064
Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268
Pinol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994. doi:10.1001/jama.293.16.1986
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158:527–535. doi:10.1016/S0002-9440(10)63994-6
Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:2417–2422
Shia J, Ellis NA, Paty PB et al (2003) Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 27:1407–1417
Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J (1997) Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 57:4749–4756
Thibodeau SN, French AJ, Roche PC et al (1996) Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56:4836–4840
Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The international collaborative group on hereditary nonpolyposis colorectal cancer. Gastroenterology 113:1146–1158
Shia J, Ellis NA, Klimstra DS (2004) The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch 445:431–441. doi:10.1007/s00428-004-1090-5
Salahshor S, Koelble K, Rubio C, Lindblom A (2001) Microsatellite instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 81:535–541
Liu T, Tannergard P, Hackman P et al (1999) Missense mutations in hMLH1 associated with colorectal cancer. Hum Genet 105:437–441
Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M (2004) Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? Virchows Arch 444:135–141. doi:10.1007/s00428-003-0922-z
Acharya S, Wilson T, Gradia S et al (1996) hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 93:13629–13634
Hampel H (2009) Genetic testing for hereditary colorectal cancer. Surg Oncol Clin N Am 18:687–703. doi:10.1016/j.soc.2009.08.001; 10.1016/j.soc.2009.08.001
Young J, Simms LA, Biden KG et al (2001) Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 159:2107–2116. doi:10.1016/S0002-9440(10)63062-3
Harfe BD, Minesinger BK, Jinks-Robertson S (2000) Discrete in vivo roles for the MutL homologs Mlh2p and Mlh3p in the removal of frameshift intermediates in budding yeast. Curr Bio 10:145–148
Kadyrov FA, Dzantiev L, Constantin N, Modrich P (2006) Endonucleolytic function of MutLalpha in human mismatch repair. Cell 126:297–308. doi:10.1016/j.cell.2006.05.039
Muller W, Burgart LJ, Krause-Paulus R et al (2001) The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) – results of an international collaborative study. Fam Cancer 1:87–92
Chiaravalli AM, Furlan D, Facco C et al (2001) Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 438:39–48
Chapusot C, Martin L, Bouvier AM et al (2002) Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. Br J Cancer 87:400–404. doi:10.1038/sj.bjc.6600474
Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116–129. doi:10.1136/gut.2009.206250; 10.1136/gut.2009.206250
Legolvan MP, Taliano RJ, Resnick MB (2012) Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. Hum Pathol 43:1157–1168. doi:10.1016/j.humpath.2012.03.003; 10.1016/j.humpath.2012.03.003
Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN (2005) Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for lynch syndrome. Fam Cancer 4:255–265. doi:10.1007/s10689-004-1447-6
Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257
Lindor NM, Burgart LJ, Leontovich O et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043–1048
Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788. doi:10.1200/JCO.2008.17.5950
Zhang L (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part II. The utility of microsatellite instability testing. J Mol Diagn 10:301–307. doi:10.2353/jmoldx.2008.080062; 10.2353/jmoldx.2008.080062
Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I. The utility of immunohistochemistry. J Mol Diagn 10:293–300. doi:10.2353/jmoldx.2008.080031; 10.2353/jmoldx.2008.080031
Marcus VA, Madlensky L, Gryfe R et al (1999) Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 23:1248–1255
Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J (2000) Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 36:49–54
Cunningham JM, Kim CY, Christensen ER et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780–790. doi:10.1086/323658
Dieumegard B, Grandjouan S, Sabourin JC et al (2000) Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer 82:871–880. doi:10.1054/bjoc.1999.1014
Stone JG, Robertson D, Houlston RS (2001) Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer. J Clin Pathol 54:484–487
Terdiman JP, Gum JR Jr, Conrad PG et al (2001) Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 120:21–30
Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62:3485–3492
Furukawa T, Konishi F, Shitoh K, Kojima M, Nagai H, Tsukamoto T (2002) Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 94:911–920
Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J (2010) Selection of patients with germline MLH1 mutated lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 9:167–172. doi:10.1007/s10689-009-9302-4; 10.1007/s10689-009-9302-4
Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870–6875
Deng G, Bell I, Crawley S et al (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191–195
Domingo E, Niessen RC, Oliveira C et al (1998) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24:3995–3998. doi:10.1038/sj.onc.1208569
Kambara T, Simms LA, Whitehall VL et al (2003) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53:1137–1144. doi:10.1136/gut.2003.037671
Domingo E, Laiho P, Ollikainen M et al (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41:664–668. doi:10.1136/jmg.2004.020651
Petersen GM, Brensinger JD, Johnson KA, Giardiello FM (1999) Genetic testing and counseling for hereditary forms of colorectal cancer. Cancer 86:2540–2550
Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition – update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20:269–276
Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135:419–428. doi:10.1053/j.gastro.2008.04.026; 10.1053/j.gastro.2008.04.026
Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117. doi:10.1038/ng.283; 10.1038/ng.283
Niessen RC, Hofstra RM, Westers H et al (2009) Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of lynch syndrome. Genes Chromosomes Cancer 48:737–744. doi:10.1002/gcc.20678; 10.1002/gcc.20678
Grover S, Syngal S (2009) Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 23:185–196. doi:10.1016/j.bpg.2009.02.006; 10.1016/j.bpg.2009.02.006
Dove-Edwin I, de Jong AE, Adams J et al (2006) Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without lynch syndrome. Gastroenterology 130:1995–2000. doi:10.1053/j.gastro.2006.03.018
Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–1985. doi:10.1001/jama.293.16.1979
Torrance N, Mollison J, Wordsworth S et al (2006) Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials. Br J Cancer 95:435–444. doi:10.1038/sj.bjc.6603248
Geiersbach KB, Samowitz WS (2011) Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135:1269–1277. doi:10.5858/arpa.2011-0035-RA; 10.5858/arpa.2011-0035-RA
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Coetzee, E., Algar, U., Goldberg, P. (2013). New Insights into Lynch Syndrome Diagnosis. In: Vogelsang, M. (eds) DNA Alterations in Lynch Syndrome. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6597-9_3
Download citation
DOI: https://doi.org/10.1007/978-94-007-6597-9_3
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6596-2
Online ISBN: 978-94-007-6597-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)